{"id":1532,"date":"2025-08-25T09:22:55","date_gmt":"2025-08-25T09:22:55","guid":{"rendered":"https:\/\/sitefansalaran.ir\/En\/?p=1532"},"modified":"2025-08-25T09:22:55","modified_gmt":"2025-08-25T09:22:55","slug":"gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million","status":"publish","type":"post","link":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/","title":{"rendered":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION"},"content":{"rendered":"<p style=\"text-align: justify;\">Gilead Sciences\u2019 (GILD.O) unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are delivered directly into patients.<\/p>\n<p style=\"text-align: justify;\">The acquisition will enable Kite to use Interius\u2019 platform to deliver cell therapy directly into patients, simplifying treatment processes and reducing costs, the company said.<\/p>\n<p style=\"text-align: justify;\">Kite said the deal, expected to close pending regulatory approvals, will reduce Gilead\u2019s 2025 profit per share by about 23 cents to 25 cents.<br \/>\nIn CAR T-cell therapy, a patient\u2019s T-cells, a key part of the immune system, are modified to better recognize and attack cancer cells.<\/p>\n<p>Traditional CAR T-cell therapies, including Kite\u2019s approved blood cancer treatments Yescarta and Tecartus, involve taking immune cells from a patient. These are modified in a lab, and then put back into the patient\u2019s body \u2013 a process that is both complex and expensive.<\/p>\n<p>Interius\u2019 so-called \u201cin-vivo\u201d approach uses intravenous infusion to deliver DNA directly into cells, potentially accelerating and simplifying treatments, according to the Kite.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences\u2019 (GILD.O) unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are delivered directly into patients. The acquisition will enable Kite to use Interius\u2019 platform to deliver cell therapy directly into patients, simplifying treatment processes and reducing [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1533,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[382,381],"class_list":{"0":"post-1532","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sitefansalaran-industry-news","8":"tag-gilead-sciences-gild-o-unit-kite-pharma","9":"tag-gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.7 (Yoast SEO v25.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION - sitefansalarn<\/title>\n<meta name=\"description\" content=\"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION\" \/>\n<meta property=\"og:description\" content=\"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/\" \/>\n<meta property=\"og:site_name\" content=\"sitefansalarn\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T09:22:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"719\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"dorost\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"dorost\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/\",\"url\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/\",\"name\":\"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION - sitefansalarn\",\"isPartOf\":{\"@id\":\"https:\/\/sitefansalaran.ir\/En\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg\",\"datePublished\":\"2025-08-25T09:22:55+00:00\",\"author\":{\"@id\":\"https:\/\/sitefansalaran.ir\/En\/#\/schema\/person\/683165262506af1443eb7897426c3ac4\"},\"description\":\"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION\",\"breadcrumb\":{\"@id\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#primaryimage\",\"url\":\"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg\",\"contentUrl\":\"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg\",\"width\":1280,\"height\":719},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sitefansalaran.ir\/En\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sitefansalaran.ir\/En\/#website\",\"url\":\"https:\/\/sitefansalaran.ir\/En\/\",\"name\":\"sitefansalarn\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sitefansalaran.ir\/En\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/sitefansalaran.ir\/En\/#\/schema\/person\/683165262506af1443eb7897426c3ac4\",\"name\":\"dorost\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sitefansalaran.ir\/En\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9e1aef8b9f557ebfb9bc35a62b323041f36a130f4ef6ef775b3cdb80a3cfc4a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9e1aef8b9f557ebfb9bc35a62b323041f36a130f4ef6ef775b3cdb80a3cfc4a?s=96&d=mm&r=g\",\"caption\":\"dorost\"},\"url\":\"https:\/\/sitefansalaran.ir\/En\/author\/adminsitefan\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION - sitefansalarn","description":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/","og_locale":"en_US","og_type":"article","og_title":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION","og_description":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION","og_url":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/","og_site_name":"sitefansalarn","article_published_time":"2025-08-25T09:22:55+00:00","og_image":[{"width":1280,"height":719,"url":"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg","type":"image\/jpeg"}],"author":"dorost","twitter_card":"summary_large_image","twitter_misc":{"Written by":"dorost","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/","url":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/","name":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION - sitefansalarn","isPartOf":{"@id":"https:\/\/sitefansalaran.ir\/En\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#primaryimage"},"image":{"@id":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#primaryimage"},"thumbnailUrl":"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg","datePublished":"2025-08-25T09:22:55+00:00","author":{"@id":"https:\/\/sitefansalaran.ir\/En\/#\/schema\/person\/683165262506af1443eb7897426c3ac4"},"description":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION","breadcrumb":{"@id":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#primaryimage","url":"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg","contentUrl":"https:\/\/sitefansalaran.ir\/En\/wp-content\/uploads\/2025\/08\/photo_2025-08-25_12-54-29.jpg","width":1280,"height":719},{"@type":"BreadcrumbList","@id":"https:\/\/sitefansalaran.ir\/En\/2025\/08\/25\/gilead-unit-to-acquire-cell-therapy-developer-interius-for-350-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sitefansalaran.ir\/En\/"},{"@type":"ListItem","position":2,"name":"GILEAD UNIT TO ACQUIRE CELL THERAPY DEVELOPER INTERIUS FOR $350 MILLION"}]},{"@type":"WebSite","@id":"https:\/\/sitefansalaran.ir\/En\/#website","url":"https:\/\/sitefansalaran.ir\/En\/","name":"sitefansalarn","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sitefansalaran.ir\/En\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sitefansalaran.ir\/En\/#\/schema\/person\/683165262506af1443eb7897426c3ac4","name":"dorost","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sitefansalaran.ir\/En\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e9e1aef8b9f557ebfb9bc35a62b323041f36a130f4ef6ef775b3cdb80a3cfc4a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9e1aef8b9f557ebfb9bc35a62b323041f36a130f4ef6ef775b3cdb80a3cfc4a?s=96&d=mm&r=g","caption":"dorost"},"url":"https:\/\/sitefansalaran.ir\/En\/author\/adminsitefan\/"}]}},"_links":{"self":[{"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/posts\/1532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/comments?post=1532"}],"version-history":[{"count":1,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/posts\/1532\/revisions"}],"predecessor-version":[{"id":1534,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/posts\/1532\/revisions\/1534"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/media\/1533"}],"wp:attachment":[{"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/media?parent=1532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/categories?post=1532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sitefansalaran.ir\/En\/wp-json\/wp\/v2\/tags?post=1532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}